BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe…
BIO KEY INTERNATIONAL INC (BKYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ET Holmdel, NJ – November 13, 2026 – BIO-key® International, Inc. (Nasdaq: BKYI), a g
How this was made
The 30-second read
Why it matters
The earnings beat on software revenue and margin could attract short‑term buying, but the overall loss and modest top‑line decline temper enthusiasm.
Market read
Micro‑cap earnings with strong software growth may trigger a short‑term rally, but broader market impact is limited.
What to watch
The company remains loss‑making and cash‑flow negative; future growth depends on sustaining government contracts.
BIO-key Q3 2026 license fee revenue rose 39% and gross margin reached 90%, while total revenue fell to $1,482,781 and a $4,502,004 deemed dividend widened the loss to common holders
License fee revenue grew 39% in the quarter, gross margin rose to 90% from 77%, and the net loss narrowed 8%. Total revenue declined from $1,549,706 to $1,482,781, hardware revenue fell sharply, and net loss available to common stockholders was $(5,388,087), or $(4.01) per share, because of a non-cash deemed dividend of $4,502,004.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, Q3 2026GAAP | $1,482,781 | – | – |
| License fees revenue, Q3 2026GAAP | $1,275,249 | – | 39% |
| Hardware revenue, Q3 2026GAAP | $12,404 | – | – |
| Services, maintenance and other revenue, Q3 2026GAAP | $195,128 | – | -27% |
| Total revenues, nine months 2026GAAP | $5,548,305 | – | 14% |
| License fees revenue, nine months 2026GAAP | $3,870,487 | – | 37% |
| Hardware revenue, nine months 2026GAAP | $1,003,302 | – | – |
| Services, maintenance and other revenue, nine months 2026GAAP | $674,516 | – | – |
| Total costs and other expenses (cost of revenue), Q3 2026GAAP | $143,373 | – | – |
| Total costs and other expenses (cost of revenue), nine months 2026GAAP | $765,624 | – | – |
| Gross profit, Q3 2026GAAP | $1,339,408 | – | 12% |
| Gross margin, Q3 2026GAAP | 90% | – | – |
| Gross profit, nine months 2026GAAP | $4,782,681 | – | 27% |
| Gross margin, nine months 2026GAAP | 86% | – | – |
| Total operating expenses, Q3 2026GAAP | $2,159,621 | -2% | 4% |
| Selling, general and administrative expenses, Q3 2026GAAP | $1,524,583 | -2% | 9% |
| Research, development and engineering expenses, Q3 2026GAAP | $635,038 | – | -7% |
| Total operating expenses, nine months 2026GAAP | $6,290,013 | – | -1% |
| Selling, general and administrative expenses, nine months 2026GAAP | $4,397,676 | – | – |
| Research, development and engineering expenses, nine months 2026GAAP | $1,892,337 | – | – |
| Operating loss, Q3 2026GAAP | $(820,213) | – | – |
| Operating loss, nine months 2026GAAP | $(1,507,332) | – | – |
| Loan fee amortization, Q3 2026GAAP | $(62,500) | – | – |
| Interest expense, Q3 2026GAAP | $(4,048) | – | – |
| Total other income (expense), net, Q3 2026GAAP | $(65,870) | – | – |
| Interest expense, nine months 2026GAAP | $(58,214) | – | – |
| Total other income (expense), net, nine months 2026GAAP | $(160,640) | – | – |
| Provision for income taxes, Q3 2026GAAP | - | – | – |
| Net loss, Q3 2026GAAP | $(886,083) | – | narrowed 8% |
| Net loss, nine months 2026GAAP | $(1,667,972) | – | improved 42% |
| Deemed dividend related to warrant inducement, Q3 2026GAAP | $(4,502,004) | – | – |
| Net loss available to common stockholders, Q3 2026GAAP | $(5,388,087) | – | – |
| Net loss available to common stockholders, nine months 2026GAAP | $(6,169,976) | – | – |
| Basic and diluted loss per common share, Q3 2026GAAP | $(4.01) | – | – |
| Basic and diluted loss per common share, nine months 2026GAAP | $(5.37) | – | – |
| Other comprehensive loss, foreign currency translation adjustment, Q3 2026GAAP | $(62,409) | – | – |
| Comprehensive loss, Q3 2026GAAP | $(5,450,496) | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $2,219,428 | – | – |
| Total assets, September 30, 2026GAAP | $8,843,672 | – | – |
| Total stockholders' equity, September 30, 2026GAAP | $6,541,642 | – | – |
| Working capital, September 30, 2026other | $3.1M | – | – |
| EMESA region revenue, Q3 2026other | $924,760 | – | 39% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| License fees (product line)The filing says license fee revenue reflected several new customer deployments and represented 86% of total revenues vs. 59% in Q3'25. | $1,275,249 | – | 39% |
| Services, maintenance and other (product line)The filing attributes the decrease primarily to the timing of service agreement renewals and the shift to Partner-led Software-as-a-Service and subscription deployments. | $195,128 | – | -27% |
| Hardware (product line)The filing says new customer orders in Q3'26 were primarily software-only, while Q3'25 reflected a large hardware deployment by a long-term customer and expanded hardware deployments by several existing customers. | $12,404 | – | – |
| EMESA region (Europe, Middle East and South America), total revenueThe filing says EMESA license fee revenues more than doubled to $903,249 from $446,480 in Q3'25. | $924,760 | – | 39% |
| EMESA region, license fee revenueThe filing says EMESA license fee revenues more than doubled from $446,480 in Q3'25. | $903,249 | – | – |
Qualitative outlook for Q4 2026 and 2027 (no numeric guidance printed) outlook
- NoteBIO-key anticipates a solid finish to 2026 and a strong start to 2027, supported by recent Middle East government wins, a growing pipeline of government and financial sector opportunities, expanding deployments with existing customers, and anticipated annual license renewals.
Capital returns
- During Q3 2026 BIO-key completed a warrant inducement transaction in August, described as providing $2.5M in gross proceeds, and recorded a non-cash deemed dividend of $4,502,004 related to it.
- During Q3 2026 BIO-key retired the remaining balance of its note payable through exchanges for common stock.
- BIO-key effected a 1-for-10 reverse stock split effective April 30, 2026. Per share amounts reflect the split.
- No share repurchases or cash dividends are reported in the filing.
What drove it
- The filing says license fee growth offset lower hardware and services revenue, which the company describes as more variable due to project timing.
- The filing says gross margin improved to 90% from 77% in Q3'25 because of the higher mix of license fee revenue.
- The filing says the Q3 2026 net loss narrowed, reflecting higher gross profit and lower operating expenses.
- The filing says the 9M 2026 net loss improved 42%, reflecting higher revenue and gross profit and lower operating expenses.
- The filing says SG&A increased 9% in Q3 2026, reflecting higher administrative personnel costs and costs related to the company's annual meeting.
- The filing says R&D expenses decreased 7% in Q3 2026, primarily reflecting lower personnel costs.
- The filing says the company added three new Middle East government customers in October 2026 and that eight new Middle East region customers were added in the past seven months.
- The filing says Cipher, a Prosegur company, is integrating BIO-key's IAM and biometric authentication solutions into its cybersecurity portfolio in Portugal.
- The filing says BIO-key received FIDO Alliance full certification for its Passkey:YOU authentication.
Concerns
- Total revenues were $1,482,781 in Q3 2026 vs. $1,549,706 in Q3 2025, a decline the filing describes as modestly lower revenue.
- Hardware revenue fell to $12,404 from $363,642, and services revenue decreased 27%.
- Net loss available to common stockholders was $(5,388,087), or $(4.01) per share, because of the $4,502,004 non-cash deemed dividend. The filing shows $(964,849), or $(1.44) per share, in Q3 2025.
- Weighted average common shares outstanding were 1,342,766 in Q3 2026 vs. 671,820 in Q3 2025, reflecting the warrant inducement and note exchanges described in the filing.
- The safe harbor statement lists as risks the company's history of losses and limited revenue, its ability to raise additional capital, and its ability to continue as a going concern.
- The safe harbor statement refers to the suspension of trading of the company's common stock on the Nasdaq Capital Market from May 13, 2026 until reinstatement effective July 8, 2026, and to Nasdaq Hearing Panel monitoring through July 6, 2027.
- The safe harbor statement lists a temporary loss of the use of a Form S-3 registration statement.
What to watch
- Whether license fee revenue growth continues in Q4 2026, given the company's statement that it anticipates a solid finish to 2026.
- Conversion of the Middle East government wins and the Central Bank of Jordan selection into recognized license revenue.
- Hardware and services revenue, given the company's comment that Q3 2026 hardware orders were primarily software-only.
- Whether SG&A growth reverses after the 9% increase in Q3 2026.
- Gross margin trajectory after the company's statement that it has improved for five consecutive quarters.
- Cash position of $2,219,428 and working capital trends, given the company's statement that it is effectively free of debt.
- Progress on the Nasdaq monitoring period and any further listing or filing compliance matters described in the safe harbor statement.
- Commercial uptake of the Passkey:YOU and AI agent identity offering described as a new market opportunity.
Balance sheet and cash flow
- Cash and cash equivalents were $2,219,428 at September 30, 2026, compared with $2,694,663 at December 31, 2025.
- Accounts receivable, net was $2,354,935 at September 30, 2026, compared with $1,220,822 at December 31, 2025.
- Inventory was $367,063 at September 30, 2026, compared with $370,879 at December 31, 2025.
- Total current assets were $5,278,871 at September 30, 2026, compared with $4,537,687 at December 31, 2025.
- Investments were $2,500,000 at both September 30, 2026 and December 31, 2025.
- Total liabilities were $2,302,030 at September 30, 2026, compared with $3,196,510 at December 31, 2025.
- Note payable was $0 at September 30, 2026, compared with $604,102 at December 31, 2025. The filing describes the company as effectively free of debt other than a $12k bank obligation in Europe.
- Stockholders' equity was $6,541,642 at September 30, 2026, compared with $4,334,878 at June 30, 2026 and $5,106,805 at December 31, 2025.
- Working capital was $3.1M at September 30, 2026, compared with $0.8M at June 30, 2026 and $1.4M at December 31, 2025.
- Operating cash flow and free cash flow are not reported in the filing.
Analysis
BIO-key reported Q3 2026 total revenues of $1,482,781 against $1,549,706 a year earlier, a decline the company attributes to lower hardware and services revenue offsetting license fee growth. License fee revenue rose 39% to $1,275,249 and rose to 86% of total revenue from 59%. Hardware revenue fell to $12,404 from $363,642, which the filing links to Q3 2026 orders being primarily software-only, and services revenue fell 27% to $195,128. The nine-month figures show the same pattern at a larger scale: total revenues rose 14% to $5,548,305, with license fees up 37% to $3,870,487, while hardware and services declined.
Margin and cost lines moved in the same direction as the mix shift. Gross profit rose 12% to $1,339,408 in Q3 2026, and gross margin reached 90% against 77%. Nine-month gross margin was 86% against 77%. Operating expenses were $2,159,621, up 4% year on year and down 2% from $2,203,445 in Q2 2026. Within that, SG&A rose 9% to $1,524,583, which the filing ties to administrative personnel costs and annual meeting costs, while R&D fell 7% to $635,038. The operating loss narrowed to $(820,213) from $(892,190), and the net loss narrowed 8% to $(886,083). Nine-month net loss improved 42% to $(1,667,972).
The headline per-share figure is distorted by a non-cash deemed dividend of $4,502,004 tied to the August warrant inducement. Including it, net loss available to common stockholders was $(5,388,087), or $(4.01) per share, against $(964,849), or $(1.44) per share, in Q3 2025. Weighted average shares were 1,342,766 against 671,820, and the filing presents the reverse split as applied to all periods. Readers comparing per-share losses should note that the Q3 2025 share count is reported after the 1-for-10 reverse split.
The balance sheet changed materially. Stockholders' equity rose to $6,541,642 from $4,334,878 at June 30, 2026 and $5,106,805 at December 31, 2025, and the filing attributes the increase to $2.5M of gross proceeds from the warrant inducement. Cash was $2,219,428, down from $2,694,663 at year-end 2025, while accounts receivable rose to $2,354,935 from $1,220,822. The note payable was retired through exchanges for common stock, and the filing describes the company as effectively free of debt apart from a $12k bank obligation in Europe. Working capital was $3.1M at September 30, 2026.
On guidance, the company gave no numeric targets. It states that it anticipates a solid finish to 2026 and a strong start to 2027, citing Middle East government wins, the pipeline, expanded deployments and expected annual license renewals. The safe harbor statement also lists going concern, capital raising, Nasdaq monitoring and S-3 eligibility as risks, and these should be read alongside the improved results.
Management, verbatim
Our Q3'26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3'26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.
Mike DePasquale, CEO
More importantly, we believe the foundation we are building today, with marquee government and financial customers, growing high-margin software revenue, a streamlined cost structure and a cleaner balance sheet, sets the stage for an exciting 2027.
Mike DePasquale, CEO
Not in the filing
stated, not guessed- Prior-quarter (Q2 2026) values for total revenues, license fees, hardware, services, cost of revenue, gross profit and gross margin are not printed as line items.
- Percentage change for total revenues in Q3 2026 and for total revenues, gross profit and operating loss in nine months 2026 is not printed as a line-item percentage; the filing only prints the total revenue dollar figures in the table and text.
- Percentage change for hardware and services revenue on a nine-month basis, and for cost of revenue lines, is not printed.
- Percentage change for gross margin is not printed; the filing states improvement from 77% to 90% without a basis point figure.
- Percentage change for operating loss and net loss available to common stockholders is not printed.
- Prior-year figures for the deemed dividend are not printed (the table shows a dash).
- Operating cash flow, investing cash flow and free cash flow are not reported.
- Quarter-end cash, debt and total assets for Q2 2026 are not printed in the filing.
- Q2 2026 gross margin is not printed; the filing mentions a five-quarter improvement from 73% in Q2'25 to 90% in Q3'26 without the intervening quarterly figures.
- The prior outlook covered the second half of 2026 only and gave no figures for the third quarter, so there is nothing to compare with this quarterly release.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BIO-key International Inc. (Nasdaq: BKYI) filed a Form 8‑K reporting its Q3 2026 financial results, emphasizing software license fee growth and margin expansion.
Ticker impact
Q3'26 results show 39% license fee revenue growth, gross margin up to 90% and net loss narrowing, indicating improving profitability.
likely upward pressure as investors price in higher recurring software revenue and reduced losses
The earnings release provides fresh, material data on revenue growth and margin improvement, which are key drivers for price moves in micro‑cap stocks.
Market effects
Shows strength in the IAM and biometric authentication niche, potentially boosting peer sentiment.
Highlights growing demand in the Middle East and Europe, which may benefit other security vendors operating there.
Limited to niche security segment; broader market impact is modest.
Counterpoint
Despite margin gains, total revenue fell year‑over‑year and hardware/service decline may signal underlying demand weakness.
Key entities
- companyBIO-key International Inc.
Provider of identity and access management and biometric authentication solutions.
- customerCentral Bank of Jordan
New government client for biometric authentication initiatives.



